Despite the spread of state legislation requiring breast density notification, a recent study has deemed supplemental ultrasonography (US) an expensive supplementary screening method that provides “relatively small benefits.”

NeuroLaunch, the first major worldwide program for neuroscience technology businesses, is taking Atlanta by storm in a rolling 90-day program aimed to give participants and their companies the tools needed to succeed, including seed funding, mentorship, and other resources, such as access to top research centers.

Studies examining the diagnostic accuracy of MRI in distinguishing normal from abnormal extra-cranial nerves yield mixed results, according to a recent literature review published this month in the American Journal of Roentgenology.

Adding a multidetector CT-based grading scale system when examining splenic injury patients at triage yields better results for providers making care decisions, according to a study published online Dec. 3 in Radiology. 

A $4 million boon is going to Waltham, Mass.-based biomedical company XTuit Pharmaceuticals. The cancer therapy researchers behind XTuit plan to raise an additional $6 million in investments, according to a recent filing with the U.S. Securities and Exchange Commission.

A novel PET technique combining a diagnostic radionuclide with a therapeutic agent can now map the potential results of therapy for advanced renal cell carcinoma, according to a study published Dec. 4 in the Journal of Nuclear Medicine. 

The genomics market is expected to grow at an annual compound growth rate of 7.28 percent from 2013 to 2018, according to a recent market report from market research firms Infiniti Research Limited and TechNavio. 

The diagnostic imaging markets in Brazil, Russia, India and China—known as the BRIC markets, are expected to grow at a compound annual growth rate of 10.5 percent, reaching $7.6 billion within the next four years.